5-Year survival data of durvalumab after chemoradiotherapy for unresectable stage III NSCLC - an update from the PACIFIC Study
Authors
de Wit, M.Spigel, D.
Faivre-Finn, Corinne
Gray, J.
Vicente, D.
Planchard, D.
Paz-Ares, L.
Vansteenkiste, J.
Garassino, M.
Hui, R.
Quantin, X.
Rimner, A.
Wu, Y. L.
Ozguroglu, M.
Lee, K. H.
Kato, T.
Macpherson, E.
Newton, M.
Thiyagarajah, P.
Antonia, S
Reck, M.
Affiliation
Vivantes Klinikum Neukoelln, BerlinIssue Date
2021